Literature DB >> 22427152

The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC).

Giuseppe Carrà1, Sonia Johnson, Paul Bebbington, Matthias C Angermeyer, Dirk Heider, Traolach Brugha, Jean-Michel Azorin, Mondher Toumi.   

Abstract

Relatively little is known about rates of comorbid drug and alcohol problems in people with schizophrenia outside the USA. Most studies have recruited from single countries. Newly available data provided an unmatched opportunity to investigate the prevalence of comorbid dependence on alcohol and other psychoactive substances in people with schizophrenia in France, Germany and the UK at the same time. The European Schizophrenia Cohort study data set used semi-structured clinical interviews to establish DSM-IV diagnoses. 1,208 patients were interviewed in nine centres. The lifetime rate for comorbid dependence on any substance was highest in the UK (35 %), but considerably lower in Germany (21 %) and in France (19 %), and generally more than double the past-year rates. Dependence on alcohol and on other psychoactive substances showed similar variations (comorbid alcohol dependence: UK 26 %; Germany 18 %; France 14 %; comorbid drug dependence: UK 18 %; Germany 8 %; France 7 %). Differences within countries persisted after controlling for individual characteristics. The relative odds of dependence were higher than in the general population, but varied between countries and centres. Dependence disorders are a common problem in people with schizophrenia in Western Europe, although effective service configurations have yet to be developed. Overall, these European rates are less than those reported from the USA. Research comparing people with current comorbidity with those who are no longer dependent is needed.

Entities:  

Mesh:

Year:  2012        PMID: 22427152     DOI: 10.1007/s00406-012-0305-z

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  30 in total

1.  Rural and urban differences in patients with a dual diagnosis.

Authors:  K T Mueser; S M Essock; R E Drake; R S Wolfe; L Frisman
Journal:  Schizophr Res       Date:  2001-03-01       Impact factor: 4.939

2.  Effects of training community staff in interventions for substance misuse in dual diagnosis patients with psychosis (COMO study): cluster randomised trial.

Authors:  S Johnson; G Thornicroft; S Afuwape; M Leese; I R White; E Hughes; S Wanigaratne; H Miles; T Craig
Journal:  Br J Psychiatry       Date:  2007-11       Impact factor: 9.319

Review 3.  Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK. A systematic review.

Authors:  Giuseppe Carrà; Sonia Johnson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-11-13       Impact factor: 4.328

4.  Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization.

Authors:  Daniel J Foti; Roman Kotov; Lin T Guey; Evelyn J Bromet
Journal:  Am J Psychiatry       Date:  2010-05-17       Impact factor: 18.112

Review 5.  Substance use disorders: Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and International Classification of Diseases, tenth edition (ICD-10).

Authors:  Deborah Hasin; Mark L Hatzenbuehler; Katherine Keyes; Elizabeth Ogburn
Journal:  Addiction       Date:  2006-09       Impact factor: 6.526

Review 6.  Alcohol use disorders in EU countries and Norway: an overview of the epidemiology.

Authors:  Jürgen Rehm; Robin Room; Wim van den Brink; Frank Jacobi
Journal:  Eur Neuropsychopharmacol       Date:  2005-08       Impact factor: 4.600

7.  Substance abuse and suicide risk among adolescents.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Massimo Biondi; Alberto Siracusano; Massimo Di Giannantonio; Giancarlo Giupponi; Mario Amore; David Lester; Paolo Girardi; Anne Maria Möller-Leimkühler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-01-31       Impact factor: 5.270

8.  Per capita alcohol consumption and all-cause mortality in 14 European countries.

Authors:  T Norström
Journal:  Addiction       Date:  2001-02       Impact factor: 6.526

Review 9.  Detection of substance use disorders in severely mentally ill patients.

Authors:  R E Drake; A I Alterman; S R Rosenberg
Journal:  Community Ment Health J       Date:  1993-04

10.  Training in dual diagnosis interventions (the COMO Study): randomised controlled trial.

Authors:  Elizabeth Hughes; Shamil Wanigaratne; Kevin Gournay; Sonia Johnson; Graham Thornicroft; Emily Finch; Jane Marshall; Neil Smith
Journal:  BMC Psychiatry       Date:  2008-02-27       Impact factor: 3.630

View more
  17 in total

1.  The prevalence of metabolic syndrome in people with severe mental illness: a mediation analysis.

Authors:  Giuseppe Carrà; Francesco Bartoli; Daniele Carretta; Cristina Crocamo; Alberto Bozzetti; Massimo Clerici; Paul E Bebbington
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-02-22       Impact factor: 4.328

2.  Schizophrenia: from risk genes to outcome and comorbidity.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-10       Impact factor: 5.270

3.  A further evaluation of decision-making under risk and under ambiguity in schizophrenia.

Authors:  Guillaume Fond; Sophie Bayard; Delphine Capdevielle; Jonathan Del-Monte; Nawale Mimoun; Alexandra Macgregor; Jean-Philippe Boulenger; Marie-Christine Gely-Nargeot; Stéphane Raffard
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-05-26       Impact factor: 5.270

4.  Association Study of OPRM1 Gene in a Sample of Schizophrenia Patients With Alcohol Dependence or Abuse.

Authors:  Marie N S Gendy; Clement Zai; Bernard Le Foll; James L Kennedy
Journal:  Can J Addict       Date:  2019-12

5.  Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States.

Authors:  Ronald C Kessler; Maria Petukhova; Nancy A Sampson; Alan M Zaslavsky; Hans-Ullrich Wittchen
Journal:  Int J Methods Psychiatr Res       Date:  2012-08-01       Impact factor: 4.035

6.  Do patient and ward-related characteristics influence the use of coercive measures? Results from the EUNOMIA international study.

Authors:  Lucie Kalisova; Jiri Raboch; Alexander Nawka; Gaia Sampogna; Libor Cihal; Thomas W Kallert; Georgi Onchev; Anastasia Karastergiou; Valeria Del Vecchio; Andrzej Kiejna; Tomasz Adamowski; Francisco Torres-Gonzales; Jorge A Cervilla; Stephan Priebe; Domenico Giacco; Lars Kjellin; Algirdas Dembinskas; Andrea Fiorillo
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-04-16       Impact factor: 4.328

7.  Factors Affecting the Management of Somatic Comorbidity in Tunisian Patients with Schizophrenia.

Authors:  Jihene Ben Thabet; Nada Charfi; Wafa Dalhoum; Sourour Yaich; Manel Maâlej Bouali; Sana Omri; Nasreddine Zouari; Lobna Zouari; Jamel Damak; Mohamed Maâlej
Journal:  Psychiatr Q       Date:  2019-03

8.  Effects of nicotine on social cognition, social competence and self-reported stress in schizophrenia patients and healthy controls.

Authors:  Katharina Drusch; Agnes Lowe; Katrin Fisahn; Jürgen Brinkmeyer; Francesco Musso; Arian Mobascher; Tracy Warbrick; John Shah; Christian Ohmann; Georg Winterer; Wolfgang Wölwer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-10-19       Impact factor: 5.270

9.  Depression after stroke and risk of mortality: a systematic review and meta-analysis.

Authors:  Francesco Bartoli; Nicoletta Lillia; Annamaria Lax; Cristina Crocamo; Vittorio Mantero; Giuseppe Carrà; Elio Agostoni; Massimo Clerici
Journal:  Stroke Res Treat       Date:  2013-03-07

10.  Association between schizophrenia and urinary calculi: a population-based case-control study.

Authors:  Shih-Ping Liu; Ching-Chun Lin; Herng-Ching Lin; Yi-Hua Chen; Hong-Jeng Yu
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.